Abstract
We used radiolabelled monoclonal antibodies (MoAbs) to prove disease persistence after treatment for ovarian carcinoma. Twelve patients with histologically confirmed ovarian carcinoma were studied. They received 5 mCi (1 mg) of iodine-131-B72.3 by intravenous injection before and after a complete course of chemotherapy. Images were obtained with a LFOV gamma camera 2 h after MoAb administration and daily up to 6 days. Before treatment 8 patients had a true positive scan. Questionable antibody uptake was observed in 2 patients while 1 had a true negative scan and 1 a false-negative examination. After treatment the therapeutic response was evaluated. Five patients had partial remission and antibody scan showed persistence of disease in all patients except 1. Four patients showed progression of the disease and 1 no change. The antibody scan was positive in 4 and questionable in 1. Two patients had complete remission and negative antibody scans. Computed tomography (CT) could not always discriminate postoperative fibrosis from tumour lesions, especially when the peritoneum was involved in the disease. High serum levels of tumour markers were constantly associated with the presence of tumour lesions, but normal values did not guarantee absence of disease. We conclude than the antibody scan is complementary to CT and serum tumor markers in the definition of therapeutic response.
This is a preview of subscription content, log in via an institution to check access.
References
Chatal JF, Fumoleau P, Saccavini JC, Thedrez P, Curtet C, Bianco-Arco A, Chetanneau A, Peltier P, Kremer M, Guillard Y (1987) Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med 28:1807–1819
Colcher D, Horan Hand P, Nuti M, Schlom J (1981) A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78:3199–3203
Epenetos AA, Shepherd J, Britton KE, Hawkins L, Nimmon CC, Taylor-Papadimitriou J, Durbin H, Malpas JS, Mather S, Ganowska M, Duke D, Bodner WF (1984) Radioimmunodiagnosis of ovarian cancer using 123I-labelled tumor associated monoclonal antibodies. Cancer Detect Prev 7:45–49
Ferroni P, Milenic DE, Roselli M, Schlom J, Colcher D (1990) Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies. Nucl Med Biol (in press)
Goldenberg DM (1989) Future role of radiolabelled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 19:332–339
Granowska M, Shepherd J, Britton KE, Ward B, Mather S, Taylor-Papadimitriou J, Epenetos AA, Carrol MJ, Nimmon CC, Hawkins LA, Slevin M, Flatman W, Horne T, Burchel V, Durbin H, Bodmer W (1984) Ovarian cancer: diagnosis using 123I-monoclonal antibody in comparison with surgical findings. Nucl Med Commun 5:485–499
Granowska M, Nimmon CC, Britton KE, Crowther M, Mather SI, Slevin ML, Shepherd JH (1988) Kinetic analysis and probability mapping applied to the detection of ovarian cancer by radioimmunoscintigraphy. J Nucl Med 29:599–607
Johnson VG, Schlom J, Paterson AJ, Bennet J, Magnani JL, Colcher D (1986) Analysis of a human tumor-associated glycoprotein (TAG 72) identified by monoclonal antibody B72.3. Cancer Res 46:850–857
Larson SM, Carrasquillo JP, Reynolds JC (1984) Radioimmunodetection and radioimmunotherapy. Cancer Invest 2:363–381
Lastoria S, D'Amico P, Mansi L, Giordano GG, Rossiello R, Schlom J, Pace E, Panza N, Pacilio G, Salvatore M (1988) A prospective imaging study of 131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: preliminary report. Nucl Med Commun 9:347–356
Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. Semin Oncol 11:251–263
Pateisky N, Philipp K, Skodler WD, Czerwenka K, Hamilton G, Burchell J (1985) Radioimmunodetection in patients with suspected ovarian cancer. J Nucl Med 26:1369–1376
Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J (1986) Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118–3124
Author information
Authors and Affiliations
Additional information
Preliminary results were presented at the 2nd International Conference on Diagnosis and Therapy with Monoclonal Antibodies, Naples, Italy, 26–28 April 1990
Rights and permissions
About this article
Cite this article
Camera, L., Del Vecchio, S., Petrillo, A. et al. Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. Eur J Nucl Med 18, 269–273 (1991). https://doi.org/10.1007/BF00186652
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00186652